Skip to main content
Journal cover image

Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.

Publication ,  Journal Article
Patel, K; Gordon, SC; Jacobson, I; Hézode, C; Oh, E; Smith, KM; Pawlotsky, J-M; McHutchison, JG
Published in: J Hepatol
December 2004

BACKGROUND/AIMS: In chronic hepatitis C (CHC) infection, a liver biopsy provides important information that guides treatment decisions, but is invasive, expensive and associated with possible complications. Extracellular matrix remodeling proteins may be useful non-invasive markers of fibrosis. The aim of this study was to evaluate the diagnostic accuracy of a panel of these markers in CHC patients, develop a predictive algorithm that differentiates no/mild (METAVIR F0-F1) from moderate/severe (F2-F4) fibrosis, and validate the model in external cohorts. METHODS: A combination of matrix markers were initially evaluated and optimized in 294 CHC patients from a single center, and validated in an external cohort of 402 patients. RESULTS: Hyaluronic acid, TIMP-1 and alpha2-macroglobulin were selected as having the best predictive accuracy for F2-F4 fibrosis (combined AUROC = 0.831). At an index cut-off >0.36 and prevalence for F2-F4 of 52%, results in all 696 patients indicated positive and negative predictive values of 74.3 and 75.8% with an accuracy of 75%. CONCLUSIONS: The three-marker panel may reliably differentiate CHC patients with moderate/severe fibrosis from those with no/mild fibrosis, although accurate delineation between stages was not possible. Prospective studies are required to determine the potential utility of the marker panel in guiding treatment decisions and following disease progression.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Hepatol

DOI

ISSN

0168-8278

Publication Date

December 2004

Volume

41

Issue

6

Start / End Page

935 / 942

Location

Netherlands

Related Subject Headings

  • alpha-Macroglobulins
  • Tissue Inhibitor of Metalloproteinase-1
  • Severity of Illness Index
  • Serologic Tests
  • Predictive Value of Tests
  • Middle Aged
  • Male
  • Liver Cirrhosis
  • Hyaluronic Acid
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Patel, K., Gordon, S. C., Jacobson, I., Hézode, C., Oh, E., Smith, K. M., … McHutchison, J. G. (2004). Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol, 41(6), 935–942. https://doi.org/10.1016/j.jhep.2004.08.008
Patel, Keyur, Stuart C. Gordon, Ira Jacobson, Christophe Hézode, Esther Oh, Katie M. Smith, Jean-Michel Pawlotsky, and John G. McHutchison. “Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.J Hepatol 41, no. 6 (December 2004): 935–42. https://doi.org/10.1016/j.jhep.2004.08.008.
Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol. 2004 Dec;41(6):935–42.
Patel, Keyur, et al. “Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.J Hepatol, vol. 41, no. 6, Dec. 2004, pp. 935–42. Pubmed, doi:10.1016/j.jhep.2004.08.008.
Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, Pawlotsky J-M, McHutchison JG. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol. 2004 Dec;41(6):935–942.
Journal cover image

Published In

J Hepatol

DOI

ISSN

0168-8278

Publication Date

December 2004

Volume

41

Issue

6

Start / End Page

935 / 942

Location

Netherlands

Related Subject Headings

  • alpha-Macroglobulins
  • Tissue Inhibitor of Metalloproteinase-1
  • Severity of Illness Index
  • Serologic Tests
  • Predictive Value of Tests
  • Middle Aged
  • Male
  • Liver Cirrhosis
  • Hyaluronic Acid
  • Humans